Tarsus Pharmaceuticals, Inc. SEC filings TARS
Tarsus Pharmaceuticals, Inc. has 676 filings in SEC EDGAR's recent list, going back to Aug 7, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K/A | Amended current report | Oct 13, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Other events
|
Sep 10, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 6, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 6, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 13, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jul 8, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 23, 2026 | Feb 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 18, 2026 | Feb 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2025 | Nov 4, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Results of operations
|
May 1, 2025 | May 1, 2025 |
| 8-K |
Current report
Other events
|
Mar 18, 2025 | Mar 14, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Mar 13, 2025 | Mar 12, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 25, 2025 | Feb 25, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 17, 2025 | Jan 15, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Material agreement
|
Dec 19, 2024 | Dec 16, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 5, 2024 | Nov 1, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Apr 23, 2024 | Apr 19, 2024 |
| 8-K |
Current report
Other events
|
Mar 5, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Mar 1, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2024 | Feb 27, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 18, 2024 | Jan 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Other events
|
Dec 11, 2023 | Dec 11, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 2, 2023 | Jul 31, 2023 |
| 8-K |
Current report
Other events
|
Jul 31, 2023 | Jul 31, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 25, 2023 | Jul 25, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 27, 2023 | Jun 22, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 15, 2023 | Jun 15, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Apr 24, 2023 | Apr 18, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Material agreement
|
Jan 5, 2023 | Jan 5, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 7, 2022 | Dec 1, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Officer or director change
|
Oct 12, 2022 | Oct 6, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2022 | Jun 16, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
May 4, 2022 | May 2, 2022 |
| 8-K |
Current report
Other events
|
May 3, 2022 | May 2, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
May 2, 2022 | May 2, 2022 |
| 8-K |
Current report
Other events
|
May 2, 2022 | May 2, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 14, 2022 | Mar 14, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Feb 2, 2022 | Feb 2, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 4, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2021 | Nov 9, 2021 |
| 8-K |
Current report
Other events
|
Nov 1, 2021 | Nov 1, 2021 |
| 8-K |
Current report
Officer or director change
|
Aug 12, 2021 | Aug 10, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2021 | Aug 4, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2021 | Jun 15, 2021 |
| 8-K |
Current report
Other events
|
Jun 21, 2021 | Jun 21, 2021 |
| 8-K |
Current report
Results of operations
|
May 11, 2021 | May 11, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 9, 2021 | Apr 8, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Material agreement, Other events
|
Mar 30, 2021 | Mar 26, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 20, 2020 | Nov 19, 2020 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 17, 2020 | Nov 17, 2020 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 20, 2020 | Oct 20, 2020 |
Showing 72 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TARS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1819790
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.